With the genetic correction, higher odds ratios (ORs) for digestive cancer risk were found for the genetic corrected levels of tumor biomarkers compared with their raw serum levels (1.57 vs. 1.65 for AFP; 1.19 vs. 1.21 for CA19–9; 1.09 vs. 1.10 for CEA, respectively). The gene discussed is AFP; the disease is neoplasm.